eCOA, eSource & Clinical Trials Market
eCOA, eSource & Clinical Trials Market Study by Electronic Clinical Outcome Assessment (eCOA), eSource, Clinical Trial Solutions, and Electronic Data Capture (EDC) from 2023 to 2033
Analysis of eCOA, eSource & Clinical Trials Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
eCOA, eSource & Clinical Trials Market Outlook (2023 to 2033)
The global eCOA, eSource & clinical trials market is valued at US$ 48 billion in 2023 and is expected to reach a market size of US$ 104 billion by the end of 2033, expanding rapidly at a CAGR of 8% over the next ten years. Worldwide demand for eCOA (electronic clinical outcome assessment) solutions is predicted to rise at a CAGR of 8.2% over the forecast period.
The difficulties of paper-based records are all addressed by eCOA solutions, which also improve patient compliance. By gathering information in an organized manner, the streamlined information provided by these solutions helps to improve the quality of the data.
Clinical trials serve as the cornerstone for the operation of pharmaceutical firms, which have been under constant pressure to fulfil the growing demand for high-quality, cost-effective treatments. Healthcare facilities, medical device manufacturers, and academic and research institutions have focused on increasing the effectiveness of clinical trials.
Clinical trials are witnessing a turmoil of changes as an increase in pharma companies places their focus on addressing the growing concerns around efficiency. Unleashing the power of digitization through eCOA, eSource, and clinical trial solutions, companies have set their focus on streamlining clinical trials, enhancing R&D efficiency, and cutting the costs of lengthy processes.
Increasing demand for the timely launch of drugs, devices, and healthcare solutions, coupled with the growing stringency of regulations for product approval, is highly likely to witness a paradigm shift in the clinical trial process. Several pharma companies and research centers are using eSources, including electronic health records (EHR), devices, apps, and direct data capture, to streamline their clinical trial processes.
A method for electronically gathering data from clinical preliminary examinations is called electronic clinical outcome assessment (eCOA). It can kindly increase the nature of research information while fulfilling administrative requirements. There is a growing demand for more clinical trials across more sites, and this need is set to proliferate over the coming years. As digital technologies could reduce clinical trial costs and streamline processes, several healthcare facilities and research centers have placed their focus on paperless ways.
Report Attributes |
Details |
|
eCOA, eSource & Clinical Trials Market Size (2023) |
US$ 48 Billion |
|
Projected Market Value (2033) |
US$ 104 Billion |
|
Global Market Growth Rate (2023 to 2033) |
8% CAGR |
|
Market Share of eCOA (Electronic Clinical Outcome Assessment) (2023) |
50% |
|
Key Companies Profiled |
|
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Which Key Aspect is Revolutionizing the eCOA, eSource & Clinical Trials Market?
“Digital Transformation of Clinical Trials”
Paper-based data collection represents a key issue for the accuracy of the data used for conducting clinical trials. As the entire clinical trial process is rigid and does not allow for much flexibility, organizations have to comply with strict protocols, and the changes are tedious to implement.
Patient adherence has emerged as a leading issue in clinical trial processes in recent years. This has paved the way for the adoption of novel technologies that have been cited as having the potential to radically change the way clinical trials are conducted. Several healthcare companies and governments are also taking initiatives to conduct clinical trials in a digital way to reduce lengthy timelines and high costs.
The increasing costs of conducting a trial and the commercial risks of failure are becoming unsustainable. Such a disruptive state has already driven the adoption of novel technologies, thereby catalyzing the digital transformation of clinical trials.
Digitization in clinical trials has enabled pharmaceutical companies to expand their reach to remote and even smaller patient groups and create enhanced protocols to test treatments. While many companies demonstrate an appetite for adopting advanced digital and mobile technologies, eCOA, eSource, & clinical trials market spending is likely to grow over the coming years.
What Can Affect Global Demand Growth for eCOA, eSource & Clinical Trials?
“Lack of Internet Connectivity, Data Security, Privacy Concerns”
It’s the right time for contract research organizations, healthcare facilities, pharmaceutical companies, and education and research institutions to get in the game of digitization, but too much dependency on technology remains a risky bet for them. While some organizations are just adopting single tools or clinical trial solutions, others have disrupted the whole value chain to skim the cream from accurate and insightful results.
Privacy issues and excessive dependency on technology continue to hinder the deployment prospects of eCOA, eSource, and clinical trial solutions. The growing penetration of bring-your-own-device (BYOD) trends in clinical trials continue to pose a threat to the safe transmission of data by healthcare providers.
Lack of internet connectivity is another key factor that is likely to impede market growth. Also, a lack of interaction between healthcare professionals and patients can lead to errors in the clinical services delivered to patients. Such factors continue to obstruct the deployment of clinical trial solutions and the use of eCOA and eSource during clinical processes.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
How Can Start-ups Settle Down in This Industry?
“New Companies Introducing Technologically Advanced Clinical Trial Solutions”
Emerging market players are offering smart digital tools to simplify clinical trials. To guarantee that expenses stay within the budget, a well-designed clinical trial is also necessary. This motivates new entrants to develop technologically advanced clinical trial solutions.
- A platform called Koneksa Compare is created by the Danish start-up, Koneksa Health to record, track, and examine actual patient-generated data and trial results. The dependability of patient-reported data can be increased by pharmaceutical R&D departments using Koneksa's electronic clinical outcome assessments (eCOAs).
Which Region Enjoys a Leading Position in the Global eCOA, eSource & Clinical Trials Market?
“North America Leading Due to Presence of Well-established Healthcare Infrastructure”
- North America accounts for 50% share of the global market in 2023.
The presence of a well-established healthcare infrastructure & prominent medical device manufacturers and an increase in medical educational institutions are driving market growth in the region. New drug development activities in the region are anticipated to be fueled by the existence of advanced research centers.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Country-wise Insights
Why is the United States Prophesized to be an Opportune Market?
“Increasing Initiatives by Key Market Players for Adoption of eClinical Platforms”
Surging demand for novel technologies in educational & research institutes will boost the demand for eCOA clinical trials in the United States. One of the main factors influencing market growth in the United States is an increase in initiatives for the adoption of eClinical platforms by major market participants.
How is the Market for eCOA, eSource & Clinical Trials Progressing in Japan?
“Increasing Patient Pool in Japan”
Extensive spending on research and development activities across Japan to spur the growth of the market in Japan. Rising need for CROs to perform clinical trials in Japan to aid the growth of the market. Increasing patient pool, outsourcing, and the flow of investments by MNCs and CROs to support clinical research and drug discovery are all expanding market expansion in Japan.
Will Germany Be a Lucrative Market Going Forward?
“Favorable Government Support for Clinical Trials”
Constant advancements in biotech medical companies, favorable government support for clinical trials, and the availability of cost-efficient medical services are boosting market value in Germany. The high R&D spending by pharmaceutical companies and rising demand for clinical trial management systems are the factors driving market growth.
Category-wise Insights
Which Solution Type is Spearheading Market Development?
“eCOA Solutions Widely Used to Efficiently Capture and Manage Clinical Information”
Based on solution type, the market is divided into eCOA (electronic clinical outcome assessment), eSource, clinical trial solutions, and electronic data capture (EDC).
- eCOA (electronic clinical outcome assessment) accounts for 50% share of the global market.
The need for electronic clinical outcome assessment solutions is anticipated to be fueled by factors such as an increase in clinical trials, efficient capture and manage clinical information, and an increase in R&D activities. Increasing externalization of clinical trial studies by major pharmaceutical and biopharmaceutical firms, rising cloud-based service demand, and expanding eCOA modalities are boosting demand for eCOA solutions.
The complexity of healthcare information management will encourage the adoption of eCOA solutions. These solutions will allow healthcare institutions to get reliable and timely health information while easing the burden on people participating in research trials.
Why is Preference for Cloud-based (SaaS) Deployment Increasing Worldwide?
“Cloud-based (SaaS) Deployment Offers Remote Access to Patients’ Medical Records”
The market is segmented into licensed enterprise (on-premise) and cloud-based (SaaS) by deployment.
- Currently, cloud-based (SaaS) deployment holds 60% share of the global market.
Cloud-based (SaaS) deployment is preferred due to its several advantages such as data centralization, scalability, cost savings, and real-time data tracking. Some of the primary features provided by cloud-based solutions include remote access to the patient's medical records and information exchange to prevent data misuse or address issues at a crucial stage of research.
Cloud-based (SaaS) deployment eliminates the need for internal maintenance. A third-party service provider maintains and stores all data in a single place, making cloud-based solutions perfect for complicated, multisite clinical research.
Competitive Landscape
Healthcare businesses are now required to develop innovative tactics to preserve their competitive advantage in the market. Major market participants are concentrating on new developments and partnerships to enhance their patient-centric technologies.
Leading companies are taking initiatives to meet the demand for efficient completion of clinical trials. They are focusing on joint ventures, product standards, and quality control to increase their market share. Key market players are investing significantly in research and development initiatives to introduce innovative solutions.
For instance :
- Mapi, a clinical outcome assessment provider allied with YPrime, a leading eClinical technology company to simplify the deployment of validated assessments migrated onto YPrime's eCOA platform, which is installed on mobile devices.
- Ochsner Health System and Pfizer have collaborated to construct a digital superhighway for clinical trials. Together the companies have employed Fast Healthcare Interoperability Resources (FHIR) to quickly transmit data from the Electronic Health Records (HER) to enhance access to experimental therapies for clinicians and patients. Collaborations continue to remain the key strategy of stakeholders to move ahead in the highly competitive and fragmented market.
Key Segments of eCOA, eSource & Clinical Trials Industry Research
-
By Solution Type :
- eCOA (Electronic Clinical Outcome Assessment)
- ePROs (Patient Reported Outcomes)
- ClinROs (Clinician Reported Outcomes)
- ObsROs (Observer Reported Outcomes)
- PerfOs (Performance Outcomes)
- eSource
- Clinical Trial Solutions
- Clinical Data Management Systems (CDMS)
- Clinical Trial Management Systems (CTMS)
- Randomization and Trial Supply Management Systems (RTMS)
- Trail Planning and Safety Solutions
- Electronic Data Capture (EDC)
- eCOA (Electronic Clinical Outcome Assessment)
-
By Deployment :
- Licensed Enterprise (On-premise)
- Cloud-based (SaaS)
-
By End User :
- Contract Research Organizations
- Hospitals & Other Healthcare Facilities
- Pharmaceutical/Biotechnology/Medical Device Companies
- Educational & Research Institutes
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Global Trends 1.3. Market Dynamics 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Global Pharmaceutical Outlook 4. Key Market Trends 5. Key Success Factors 5.1. Global Adoption Pattern 5.2. Key Deals and Contracts 6. Key Inclusions 6.1. Clinical Trial – Patient Journey 6.2. Digitization in Clinical Trials 6.3. Paper-based vs. EDC data flow 6.4. Return on Investment 6.5. Traditional Process versus eCOA Integration Process 6.6. Evolution of RTSM Technology and Terminology 6.7. Global Market – Regulations 7. Global Spending on Spending (in US$ Mn) Analysis 2018-2022 and Forecast, 2023-2033 7.1. Historical Spending (US$ Mn) Analysis, 2018-2022 7.2. Current and Future Spending (US$ Mn) Projections, 2023-2033 7.2.1. Y-o-Y Growth Trend Analysis 8. Market Background 8.1. Macro-Economic Factors 8.1.1. Increasing R&D Expenditure 8.1.2. Increasing number of Biotechnology Companies 8.1.3. Rise in ICT Spending 8.2. Forecast Factors - Relevance & Impact 8.2.1. Increase in R&D Spending 8.2.2. Rise in Healthcare IT Spending 8.2.3. Increase in Number of Clinical Trials 8.2.4. Increasing Cost of Clinical Trials 8.3. Market Dynamics 8.3.1. Drivers 8.3.2. Restraints 8.3.3. Opportunity Analysis 9. Global Spending 2018-2022 and Forecast 2023-2033, by Solution Type 9.1. Introduction / Key Findings 9.2. Historical Spending (US$ Mn) Analysis By Solution Type, 2018-2022 9.3. Current and Future Spending (US$ Mn) Analysis and Forecast By Solution Type, 2023-2033 9.3.1. eCOA (Electronic clinical Outcome assessment) 9.3.1.1. ePROs (Patient Reported Outcomes) 9.3.1.2. ClinROs (Clinician Reported Outcomes) 9.3.1.3. ObsROs (Observer reported Outcomes) 9.3.1.4. PerfOs (Performance Outcomes) 9.3.2. eSource 9.3.3. Clinical Trials Solutions 9.3.3.1. Clinical Data Management Systems (CDMS) 9.3.3.2. Clinical Trial Management Systems (CTMS) 9.3.3.3. Randomization and Trial Supply Management Systems (RTMS) 9.3.3.4. Trail Planning and Safety Solutions 9.3.4. Electronic Data Capture (EDC) 9.4. Market Attractiveness Analysis By Solution Type 10. Global Spending Analysis 2018-2022 and Forecast 2023-2033, by Deployment 10.1. Introduction / Key Findings 10.2. Historical Spending (US$ Mn) Analysis By Deployment, 2018-2022 10.3. Current and Future Spending (US$ Mn) Analysis and Forecast By Deployment, 2023-2033 10.3.1. Licensed Enterprise (On Premise) 10.3.2. Cloud-based (SaaS) 10.4. Market Attractiveness Analysis By Deployment 11. Global Spending Analysis 2018-2022 and Forecast 2023-2033, by End User 11.1. Introduction / Key Findings 11.2. Historical Spending (US$ Mn) Analysis By End User, 2018-2022 11.3. Current and Future Spending (US$ Mn) Analysis and Forecast By End User, 2023-2033 11.3.1. Contract Research Organizations 11.3.2. Hospitals & Other Healthcare Facilities 11.3.3. Pharmaceutical/Biotechnology/Medical Devices Companies 11.3.4. Educational & Research Institutes 11.4. Market Attractiveness Analysis By End User 12. Global Spending Analysis 2018-2022 and Forecast 2023-2033, by Region 12.1. Introduction 12.2. Historical Spending (US$ Mn) Analysis By Region, 2018-2022 12.3. Current and Future Spending (US$ Mn) Analysis and Forecast By Region, 2023-2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. Middle East and Africa (MEA) 12.3.5. East Asia 12.3.6. South Asia 12.3.7. Oceania 12.4. Market Attractiveness Analysis By Region 13. North America Spending Analysis 2018-2022 and Forecast 2023-2033 13.1. Introduction 13.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 13.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2023-2033 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Solution Type 13.3.3. By Deployment 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.5. Drivers and Restraints - Impact Analysis 14. Latin America Spending Analysis 2018-2022 and Forecast 2023-2033 14.1. Introduction 14.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 14.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2023-2033 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Rest of Latin America 14.3.2. By Solution Type 14.3.3. By Deployment 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.5. Drivers and Restraints - Impact Analysis 15. Europe Spending Analysis 2018-2022 and Forecast 2023-2033 15.1. Introduction 15.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 15.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2023-2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Russia 15.3.1.8. Rest of Europe 15.3.2. By Solution Type 15.3.3. By Deployment 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.5. Drivers and Restraints - Impact Analysis 16. South Asia Spending Analysis 2018-2022 and Forecast 2023-2033 16.1. Introduction 16.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 16.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2023-2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Solution Type 16.3.3. By Deployment 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.5. Drivers and Restraints - Impact Analysis 17. East Asia Spending Analysis 2018-2022 and Forecast 2023-2033 17.1. Introduction 17.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 17.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2023-2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Solution Type 17.3.3. By Deployment 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.5. Drivers and Restraints - Impact Analysis 18. Oceania Spending Analysis 2018-2022 and Forecast 2023-2033 18.1. Introduction 18.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 18.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2023-2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Solution Type 18.3.3. By Deployment 18.3.4. By End User 18.4. Market Attractiveness Analysis 18.5. Drivers and Restraints - Impact Analysis 19. Middle East and Africa Spending Analysis 2018-2022 and Forecast 2023-2033 19.1. Introduction 19.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 19.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2023-2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Turkey 19.3.1.3. Northern Africa 19.3.1.4. South Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Solution Type 19.3.3. By Deployment 19.3.4. By End User 19.4. Market Attractiveness Analysis 19.5. Drivers and Restraints - Impact Analysis 20. Emerging Countries Spending Analysis 2018-2022 and Forecast 2023-2033 20.1. Introduction 20.1.1. Market Value Proportion Analysis, By Key Countries 20.2. China Market Analysis 20.2.1. Introduction 20.2.2. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.2.2.1. By Solution Type 20.2.2.2. By Deployment 20.2.2.3. By End User 20.3. India Market Analysis 20.3.1. Introduction 20.3.2. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.3.2.1. By Solution Type 20.3.2.2. By Deployment 20.3.2.3. By End User 20.4. Brazil Market Analysis 20.4.1. Introduction 20.4.2. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.4.2.1. By Solution Type 20.4.2.2. By Deployment 20.4.2.3. By End User 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies 22. Competition Analysis 22.1. Competition Dashboard 22.2. Key Development Analysis 22.3. Competition Deep Dive 22.3.1. OpenClinica, LLC 22.3.1.1. Overview 22.3.1.2. Solution Portfolio 22.3.1.3. Analyst Commentary 22.3.2. CRF Health, Inc. 22.3.2.1. Overview 22.3.2.2. Solution Portfolio 22.3.2.3. Analyst Commentary 22.3.3. ERT Clinical 22.3.3.1. Overview 22.3.3.2. Solution Portfolio 22.3.3.3. Analyst Commentary 22.3.4. Medidata Solutions, Inc. 22.3.4.1. Overview 22.3.4.2. Solution Portfolio 22.3.4.3. Analyst Commentary 22.3.5. ArisGlobal LLC 22.3.5.1. Overview 22.3.5.2. Solution Portfolio 22.3.5.3. Analyst Commentary 22.3.6. Health Diary, Inc. 22.3.6.1. Overview 22.3.6.2. Solution Portfolio 22.3.6.3. Analyst Commentary 22.3.7. ICON plc 22.3.7.1. Overview 22.3.7.2. Solution Portfolio 22.3.7.3. Analyst Commentary 22.3.8. PAREXEL International Corporation 22.3.8.1. Overview 22.3.8.2. Solution Portfolio 22.3.8.3. Analyst Commentary 22.3.9. OmniComm Systems, Inc. 22.3.9.1. Overview 22.3.9.2. Solution Portfolio 22.3.9.3. Analyst Commentary 22.3.10. PAREXEL International Corporation 22.3.10.1. Overview 22.3.10.2. Solution Portfolio 22.3.10.3. Analyst Commentary 22.3.11. Medrio, Inc. 22.3.11.1. Overview 22.3.11.2. Solution Portfolio 22.3.11.3. Analyst Commentary 22.3.12. PAREXEL International Corporation 22.3.12.1. Overview 22.3.12.2. Solution Portfolio 22.3.12.3. Analyst Commentary 22.3.13. Medable 22.3.13.1. Overview 22.3.13.2. Solution Portfolio 22.3.13.3. Analyst Commentary 22.3.14. PAREXEL International Corporation 22.3.14.1. Overview 22.3.14.2. Solution Portfolio 22.3.14.3. Analyst Commentary 22.3.15. Oracle Corp 22.3.15.1. Overview 22.3.15.2. Solution Portfolio 22.3.15.3. Analyst Commentary 22.3.16. PAREXEL International Corporation 22.3.16.1. Overview 22.3.16.2. Solution Portfolio 22.3.16.3. Analyst Commentary 22.3.17. Medpace Holdings, Inc. 22.3.17.1. Overview 22.3.17.2. Solution Portfolio 22.3.17.3. Analyst Commentary 22.3.18. PAREXEL International Corporation 22.3.18.1. Overview 22.3.18.2. Solution Portfolio 22.3.18.3. Analyst Commentary 22.3.19. Covance, Inc. 22.3.19.1. Overview 22.3.19.2. Solution Portfolio 22.3.19.3. Analyst Commentary 22.3.20. PAREXEL International Corporation 22.3.20.1. Overview 22.3.20.2. Solution Portfolio 22.3.20.3. Analyst Commentary 22.3.21. Bio-Optronics, Inc. 22.3.21.1. Overview 22.3.21.2. Solution Portfolio 22.3.21.3. Analyst Commentary 22.3.22. PAREXEL International Corporation 22.3.22.1. Overview 22.3.22.2. Solution Portfolio 22.3.22.3. Analyst Commentary 23. Assumptions and Acronyms Used 24. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Solution Type
Table 02: Global Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Deployment
Table 03: Global Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By End User
Table 04: Global Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Region
Table 05: North America Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 06: North America Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Solution Type
Table 07: North America Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Deployment
Table 08: North America Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By End User
Table 09: Latin America Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 10: Latin America Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Solution Type
Table 11: Latin America Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Deployment
Table 12: Latin America Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By End User
Table 13: Europe Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 14: Europe Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Solution Type
Table 15: Europe Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Deployment
Table 16: Europe Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By End User
Table 17: South Asia Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 18: South Asia Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Solution Type
Table 19: South Asia Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Deployment
Table 20: South Asia Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By End User
Table 21: East Asia Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 22: East Asia Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Solution Type
Table 23: East Asia Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Deployment
Table 24: East Asia Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By End User
Table 25: Oceania Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 26: Oceania Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Solution Type
Table 27: Oceania Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Deployment
Table 28: Oceania Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By End User
Table 29: MEA Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 30: MEA Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Solution Type
Table 31: MEA Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Deployment
Table 32: MEA Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By End User
Table 33: China Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Solution Type
Table 34: China Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Deployment
Table 35: China Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By End User
Table 36: India Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Solution Type
Table 37: India Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Deployment
Table 38: India Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By End User
Table 39: Brazil Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Solution Type
Table 40: Brazil Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Deployment
Table 41: Brazil Spending (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By End User
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Spending Share, 2023 & 2028
Figure 02: Number of FDA approved pharmaceuticals (2018-2022)
Figure 03: Global Spending Analysis (US$ Mn), 2018-2022
Figure 04: Global Spending Forecast (US$ Mn), 2023-2033
Figure 05: Spending (US$ Mn) Analysis, by eCOA segment, 2018–2022
Figure 06: Spending Y-o-Y Growth (%), by eCOA segment, 2022–2033
Figure 07: Spending (US$ Mn) Analysis, by eSource segment, 2018–2022
Figure 08: Software Spending Y-o-Y Growth (%), by eSource segment, 2022–2033
Figure 09: Spending (US$ Mn) Analysis, by segment, 2018–2022
Figure 10: Spending Y-o-Y Growth (%), by segment, 2022–2033
Figure 11: Spending (US$ Mn) Analysis, by EDC segment, 2018–2022
Figure 12: Software Spending Y-o-Y Growth (%), by EDC segment, 2022–2033
Figure 13: Spending (US$ Mn) Analysis, by Licensed Enterprise (On Premise) segment, 2018–2022
Figure 14: Spending Y-o-Y Growth (%), by Licensed Enterprise (On Premise) segment, 2022–2033
Figure 15: Spending (US$ Mn) Analysis, by Cloud Based (SaaS) segment, 2018–2022
Figure 16: Software Spending Y-o-Y Growth (%), by Cloud Based (SaaS) segment, 2022–2033
Figure 17: Spending (US$ Mn) Analysis, by Contract Research Organizations segment, 2018–2022
Figure 18: Spending Y-o-Y Growth (%), by Contract Research Organizations segment, 2022–2033
Figure 19: Spending (US$ Mn) Analysis, by Hospitals & Other Healthcare Facilities segment, 2018–2022
Figure 20: Software Spending Y-o-Y Growth (%), by Hospitals & Other Healthcare Facilities segment, 2022–2033
Figure 21: Spending (US$ Mn) Analysis, by Pharmaceutical/Biotechnology/Medical Device Companies segment, 2018–2022
Figure 22: Spending Y-o-Y Growth (%), by Pharmaceutical/Biotechnology/Medical Device Companies segment, 2022–2033
Figure 23: Spending (US$ Mn) Analysis, by Educational & Research Institutes segment, 2018–2022
Figure 24: Software Spending Y-o-Y Growth (%), by Educational & Research Institutes segment, 2022–2033
Figure 25: Global Market Attractiveness Analysis, By Solution Type
Figure 26: Global Market Attractiveness Analysis, By Deployment
Figure 27: Global Market Attractiveness Analysis, By End User
Figure 28: Global Market Attractiveness Analysis, By Region
Figure 29: North America spending share, by Solution Type (2022)
Figure 30: North America Spending, Snapshot
Figure 31: North America Spending (US$ Mn), 2018–2022
Figure 32: North America Spending (US$) & Y-o-Y Growth (%), 2023–2033
Figure 33: North America Market Attractiveness Analysis, By Solution Type
Figure 34: North America Market Attractiveness Analysis, By Deployment
Figure 35: North America Market Attractiveness Analysis, By End User
Figure 36: North America Market Attractiveness Analysis, By Country
Figure 37: Latin America spending share, by Solution Type (2022)
Figure 38: Latin America Spending, Snapshot
Figure 39: Latin America Spending (US$ Mn), 2018–2022
Figure 40: Latin America Spending (US$) & Y-o-Y Growth (%), 2023–2033
Figure 41: Latin America Market Attractiveness Analysis, By Solution Type
Figure 42: Latin America Market Attractiveness Analysis, By Deployment
Figure 43: Latin America Market Attractiveness Analysis, By End User
Figure 44: Latin America Market Attractiveness Analysis, By Country
Figure 45: Europe spending share, by Solution Type (2022)
Figure 46: Europe Spending, Snapshot
Figure 47: Europe Spending (US$ Mn), 2018–2022
Figure 48: Europe Spending (US$) & Y-o-Y Growth (%), 2023–2033
Figure 49: Europe Market Attractiveness Analysis, By Solution Type
Figure 50: Europe Market Attractiveness Analysis, By Deployment
Figure 51: Europe Market Attractiveness Analysis, By End User
Figure 52: Europe Market Attractiveness Analysis, By Country
Figure 53: South Asia spending share, by Solution Type (2022)
Figure 54: South Asia Spending, Snapshot
Figure 55: South Asia Spending (US$ Mn), 2018–2022
Figure 56: South Asia Spending (US$) & Y-o-Y Growth (%), 2023–2033
Figure 57: South Asia Market Attractiveness Analysis, By Solution Type
Figure 58: South Asia Market Attractiveness Analysis, By Deployment
Figure 59: South Asia Market Attractiveness Analysis, By End User
Figure 60: South Asia Market Attractiveness Analysis, By Country
Figure 61: East Asia spending share, by Solution Type (2022)
Figure 62: East Asia Spending, Snapshot
Figure 63: East Asia Spending (US$ Mn), 2018–2022
Figure 64: East Asia Spending (US$) & Y-o-Y Growth (%), 2023–2033
Figure 65: East Asia Market Attractiveness Analysis, By Solution Type
Figure 66: East Asia Market Attractiveness Analysis, By Deployment
Figure 67: East Asia Market Attractiveness Analysis, By End User
Figure 68: East Asia Market Attractiveness Analysis, By Country
Figure 69: Oceania spending share, by Solution Type (2022)
Figure 70: Oceania Spending, Snapshot
Figure 71: Oceania Spending (US$ Mn), 2018–2022
Figure 72: Oceania Spending (US$) & Y-o-Y Growth (%), 2023–2033
Figure 73: Oceania Market Attractiveness Analysis, By Solution Type
Figure 74: Oceania Market Attractiveness Analysis, By Deployment
Figure 75: Oceania Market Attractiveness Analysis, By End User
Figure 76: Oceania Market Attractiveness Analysis, By Country
Figure 77: MEA spending share, by Solution Type (2022)
Figure 78: MEA Spending, Snapshot
Figure 79: MEA Spending (US$ Mn), 2018–2022
Figure 80: MEA Spending (US$) & Y-o-Y Growth (%), 2023–2033
Figure 81: MEA Market Attractiveness Analysis, By Solution Type
Figure 82: MEA Market Attractiveness Analysis, By Deployment
Figure 83: MEA Market Attractiveness Analysis, By End User
Figure 84: MEA Market Attractiveness Analysis, By Country
Figure 85: Emerging Countries Spending (US$ Mn), 2018–2022
Figure 86: Emerging Countries Spending (US$) & Y-o-Y Growth (%), 2023–2033
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the current size of the eCOA, eSource & clinical trials market?
The global eCOA, eSource & clinical trials market is valued at US$ 48 billion in 2023.
What is the expected valuation of the market for 2033?
The market for eCOA, eSource & clinical trials is predicted to reach US$ 104 billion by 2033.
At what rate will the market for eCOA, eSource & clinical trials expand?
Revenue from eCOA, eSource & clinical trials is expected to rise at a CAGR of 8% through 2033.
Which is the most dominant region in the global market?
North America accounts for 50% share of the global market in 2023.
Which solution type accounts for a prominent market share?
Currently, eCOA solutions hold 50% share of the global market.
eCOA, eSource & Clinical Trials Market